Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia

Sarah A Holstein, John B. Stokes, Raymond J. Hohl

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Tyrosine kinase inhibitors (TKIs) directed against the Bcr-Abl kinase have revolutionized the treatment of chronic myelogenous leukemia (CML). Relatively little is known regarding the effects of these agents on the kidney. Clinically, there have been a handful of reports associating imatinib with acute renal failure. Preclinical reports indicate that imatinib inhibits signaling pathways which may play a role in renal injury. We report the case of a patient with imatinib-resistant CML who developed renal failure after being placed on dasatinib. When she later became resistant to dasatinib she was switched to nilotinib. Shortly thereafter, she became dialysis-independent. Second-generation Bcr-Abl TKIs may influence renal function based on differential inhibition of related tyrosine kinases.

Original languageEnglish (US)
Pages (from-to)344-347
Number of pages4
JournalLeukemia Research
Volume33
Issue number2
DOIs
StatePublished - Feb 1 2009

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Renal Insufficiency
Phosphotransferases
Kidney
Protein-Tyrosine Kinases
bcr-abl Fusion Proteins
Acute Kidney Injury
Dialysis
Wounds and Injuries
Imatinib Mesylate
Dasatinib
Therapeutics

Keywords

  • Bcr-Abl tyrosine kinase inhibitor
  • Chronic myelogenous leukemia
  • Renal failure

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia. / Holstein, Sarah A; Stokes, John B.; Hohl, Raymond J.

In: Leukemia Research, Vol. 33, No. 2, 01.02.2009, p. 344-347.

Research output: Contribution to journalArticle

@article{c09eed4dc30346a484694e6118e658bb,
title = "Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia",
abstract = "Tyrosine kinase inhibitors (TKIs) directed against the Bcr-Abl kinase have revolutionized the treatment of chronic myelogenous leukemia (CML). Relatively little is known regarding the effects of these agents on the kidney. Clinically, there have been a handful of reports associating imatinib with acute renal failure. Preclinical reports indicate that imatinib inhibits signaling pathways which may play a role in renal injury. We report the case of a patient with imatinib-resistant CML who developed renal failure after being placed on dasatinib. When she later became resistant to dasatinib she was switched to nilotinib. Shortly thereafter, she became dialysis-independent. Second-generation Bcr-Abl TKIs may influence renal function based on differential inhibition of related tyrosine kinases.",
keywords = "Bcr-Abl tyrosine kinase inhibitor, Chronic myelogenous leukemia, Renal failure",
author = "Holstein, {Sarah A} and Stokes, {John B.} and Hohl, {Raymond J.}",
year = "2009",
month = "2",
day = "1",
doi = "10.1016/j.leukres.2008.07.029",
language = "English (US)",
volume = "33",
pages = "344--347",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia

AU - Holstein, Sarah A

AU - Stokes, John B.

AU - Hohl, Raymond J.

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Tyrosine kinase inhibitors (TKIs) directed against the Bcr-Abl kinase have revolutionized the treatment of chronic myelogenous leukemia (CML). Relatively little is known regarding the effects of these agents on the kidney. Clinically, there have been a handful of reports associating imatinib with acute renal failure. Preclinical reports indicate that imatinib inhibits signaling pathways which may play a role in renal injury. We report the case of a patient with imatinib-resistant CML who developed renal failure after being placed on dasatinib. When she later became resistant to dasatinib she was switched to nilotinib. Shortly thereafter, she became dialysis-independent. Second-generation Bcr-Abl TKIs may influence renal function based on differential inhibition of related tyrosine kinases.

AB - Tyrosine kinase inhibitors (TKIs) directed against the Bcr-Abl kinase have revolutionized the treatment of chronic myelogenous leukemia (CML). Relatively little is known regarding the effects of these agents on the kidney. Clinically, there have been a handful of reports associating imatinib with acute renal failure. Preclinical reports indicate that imatinib inhibits signaling pathways which may play a role in renal injury. We report the case of a patient with imatinib-resistant CML who developed renal failure after being placed on dasatinib. When she later became resistant to dasatinib she was switched to nilotinib. Shortly thereafter, she became dialysis-independent. Second-generation Bcr-Abl TKIs may influence renal function based on differential inhibition of related tyrosine kinases.

KW - Bcr-Abl tyrosine kinase inhibitor

KW - Chronic myelogenous leukemia

KW - Renal failure

UR - http://www.scopus.com/inward/record.url?scp=56949104034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56949104034&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2008.07.029

DO - 10.1016/j.leukres.2008.07.029

M3 - Article

VL - 33

SP - 344

EP - 347

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 2

ER -